Rani Therapeutics Holdings Inc’s recently made public that its Chief Business Officer McKinley Kate acquired Company’s shares for reported $29993.0 on Dec 13 ’24. In the deal valued at $1.67 per share,17,960 shares were bought. As a result of this transaction, McKinley Kate now holds 17,960 shares worth roughly $27299.2.
Then, Imran Talat bought 10,296 shares, generating $19,974 in total proceeds. Upon buying the shares at $1.94, the Chief Executive Officer now owns 494,751 shares.
Before that, South Cone Investments Limited sold 3,829,360 shares. Rani Therapeutics Holdings Inc shares valued at $10,141,674 were divested by the 10% Owner at a price of $2.65 per share. As a result of the transaction, South Cone Investments Limited now holds 8,302,194 shares, worth roughly $12.62 million.
Oppenheimer initiated its Rani Therapeutics Holdings Inc [RANI] rating to an Outperform in a research note published on August 02, 2024; the price target was $17. A number of analysts have revised their coverage, including Maxim Group’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering RANI with “Buy” recommendation on June 13, 2024.
Price Performance Review of RANI
On Friday, Rani Therapeutics Holdings Inc [NASDAQ:RANI] saw its stock jump 4.45% to $1.52. Over the last five days, the stock has gained 7.39%. Rani Therapeutics Holdings Inc shares have risen nearly 11.31% since the year began. Nevertheless, the stocks have fallen -51.89% over the past one year. While a 52-week high of $8.75 was reached on 01/03/25, a 52-week low of $1.30 was recorded on 01/02/25. SMA at 50 days reached $1.9802, while 200 days put it at $3.3513.
Levels Of Support And Resistance For RANI Stock
The 24-hour chart illustrates a support level at 1.4467, which if violated will result in even more drops to 1.3683. On the upside, there is a resistance level at 1.6067. A further resistance level may holdings at 1.6883. The Relative Strength Index (RSI) on the 14-day chart is 41.61, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0049, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 52.13%. Stochastics %K at 29.10% indicates the stock is a holding.
How much short interest is there in Rani Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Rani Therapeutics Holdings Inc stocks on 2024-10-31, growing by 0.7 million shares to a total of 1.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.79 million shares. There was a rise of 47.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
